Highlights
- Innovative osteoanabolic agents are revolutionizing osteoporosis treatment and enhancing bone health restoration.
- FDA-approved biosimilars expand access to effective osteoporosis therapies, making treatment more affordable.
Summary and Background
Osteoporosis, marked by reduced bone density and fracture risk, mainly affects postmenopausal women and the elderly. Treatment has shifted from traditional antiresorptive therapies like bisphosphonates and hormone replacement to osteoanabolic agents that stimulate bone formation, such as teriparatide, abaloparatide, and romosozumab. The latter, a sclerostin inhibitor, offers dual anabolic and antiresorptive effects but raises cardiovascular safety concerns requiring ongoing monitoring. FDA-approved denosumab biosimilars, including Osvyrti and Jubereq, provide cost-effective alternatives, improving accessibility. Treatment now often involves sequential or combination approaches to maximize bone density gains, especially in severe cases. Research into novel molecular targets and experimental therapies hints at more personalized future care.
Advances in Treatments
Bisphosphonates remain first-line antiresorptive agents, while selective estrogen receptor modulators and hormone replacement have more limited roles due to safety concerns. Denosumab and its newly approved biosimilars broaden options for patients intolerant to bisphosphonates. Osteoanabolic drugs—teriparatide, abaloparatide, and romosozumab—show superior efficacy, especially for high-risk patients, with treatment guidelines recommending anabolic agents followed by antiresorptives. Emerging therapies include stem cell and gene approaches and novel inhibitors like cathepsin K and cytokine modulators, still in early development.
Innovations in 2024–2025
FDA approval of denosumab biosimilars Osvyrti and Jubereq marks a milestone, offering interchangeable, effective, and affordable alternatives to Prolia and Xgeva. Osteoanabolic agents continue to gain prominence, with abaloparatide and romosozumab demonstrating significant fracture risk reduction despite earlier cardiovascular safety concerns with romosozumab. Sequential and combination therapies—using anabolic agents initially then antiresorptives—are increasingly adopted to optimize outcomes, especially in severe osteoporosis.
Clinical Guidelines and Treatment Protocols
2025 guidelines emphasize personalized treatment balancing efficacy, safety, and adherence. Osteoanabolic agents remain central for patients with severe osteoporosis or prior fractures, with interest growing in oral anabolic formulations to improve compliance. Denosumab biosimilars expand therapeutic choices, supporting cost-effective individualized care. Sequential therapy starting with anabolic agents followed by antiresorptives is recommended, while reversing this sequence is discouraged. Economic factors and side effect profiles guide treatment selection. Emerging molecular targets like cathepsin K and 17β-HSD2 inhibitors may offer future options with fewer adverse effects.
Molecular Targets and Therapeutic Pathways
Key bone metabolism pathways—WNT, BMP, hedgehog, and Notch—are critical in regulating osteogenesis and remodeling. Sclerostin, an inhibitor of bone formation, is targeted by romosozumab and other developing antibodies. The RANKL/RANK/OPG axis regulates bone resorption; antiresorptives target this pathway alongside NF-κB and MAPK/ERK signaling. Cathepsin K inhibitors aim to reduce bone degradation selectively, though safety is under study. Osteoanabolic agents stimulate bone formation via PTH receptor activation or sclerostin inhibition. Additional targets like Dkk1 and 17β-HSD2 are under investigation for improved therapies with better safety profiles.
Comparative Effectiveness and Safety
New osteoanabolic agents such as romosozumab and PTH analogues offer greater efficacy in increasing bone mineral density and reducing fractures compared to traditional antiresorptives. However, cardiovascular safety concerns, especially with romosozumab, require careful patient selection and monitoring. Economic considerations and treatment adherence, influenced by administration frequency, also impact therapy choice. Cost-effectiveness analyses remain important amid rising osteoporosis care costs.
Future Directions
Research continues on novel anabolic agents, combination therapies, and innovative delivery methods including stem cell and gene therapies, although these remain experimental. New molecular targets like cathepsin K and 17β-HSD2 inhibitors are promising for safer, more effective treatment. Biosimilars such as Osvyrti and Jubereq enhance affordability and treatment options. The focus remains on precision therapies that maximize benefits while minimizing side effects, aligning with personalized medicine principles.